Literature DB >> 34992330

Hepatocyte growth factor administration increases bone soluble phosphate and alters bone chemical structure in diabetic hypertensive rats.

Kamal Awad1,2,3, Natasha G Boyes4, Ramlah Iqbal4,5, Mohamed Ahmed5, Adel Mohamed5, Pranesh Aswath1, Corey R Tomczak4, Venu Varanasi1,2.   

Abstract

Hepatocyte growth factor (HGF) is a novel potential therapy for improving bone health in patients with type II diabetes and hypertension, but its effect on the bone molecular structure is not revealed yet. Here, X-ray absorption near edge structure (XANES) spectroscopy was used to explore the effects elicited by HGF on the bone chemical structure. This study assessed local calcium (Ca) and phosphorus (P) coordination of diabetic hypertensive rat bones, each with and without HGF treatment. Results revealed that HGF has significant effects on Ca and P coordination chemistry as confirmed by presence of more soluble phosphates in the HGT-treated groups. Data indicated that treated bones have a poorly developed phosphate structure as evidenced by drastic drop in post-edge shoulder in P L2,3-edge compared to diabetic hypertensive and diabetic control bone. Presence of soluble Ca and P, products of bone resorption, with HGF treatment suggests unbalanced bone resorption and formation.

Entities:  

Year:  2021        PMID: 34992330      PMCID: PMC8725793          DOI: 10.1557/s43578-021-00300-8

Source DB:  PubMed          Journal:  J Mater Res        ISSN: 0884-1616            Impact factor:   2.909


  64 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Bone mineral density in women with essential hypertension.

Authors:  K Tsuda; I Nishio; Y Masuyama
Journal:  Am J Hypertens       Date:  2001-07       Impact factor: 2.689

3.  Hydroxyapatite-TiO(2)-based nanocomposites synthesized in supercritical CO(2) for bone tissue engineering: physical and mechanical properties.

Authors:  Mehrnaz Salarian; William Z Xu; Zhiqiang Wang; Tsun-Kong Sham; Paul A Charpentier
Journal:  ACS Appl Mater Interfaces       Date:  2014-09-23       Impact factor: 9.229

4.  Hepatocyte growth factor and p38 promote osteogenic differentiation of human mesenchymal stem cells.

Authors:  Kristina K Aenlle; Kevin M Curtis; Bernard A Roos; Guy A Howard
Journal:  Mol Endocrinol       Date:  2014-03-27

5.  Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts.

Authors:  Masatoshi Jinnin; Hironobu Ihn; Yoshihiro Mimura; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

Review 6.  Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair.

Authors:  Rachel N Frisch; Kevin M Curtis; Kristina K Aenlle; Guy A Howard
Journal:  Expert Opin Ther Targets       Date:  2016-03-21       Impact factor: 6.902

Review 7.  Insulin resistance and bone: a biological partnership.

Authors:  Caterina Conte; Solomon Epstein; Nicola Napoli
Journal:  Acta Diabetol       Date:  2018-01-15       Impact factor: 4.280

8.  X-ray absorption near-edge structure (XANES) spectroscopy study of the interaction of silver ions with Staphylococcus aureus, Listeria monocytogenes, and Escherichia coli.

Authors:  Gudrun Lisa Bovenkamp; Ulrike Zanzen; Katla Sai Krishna; Josef Hormes; Alexander Prange
Journal:  Appl Environ Microbiol       Date:  2013-08-09       Impact factor: 4.792

9.  Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension.

Authors:  Nereida K C Lima; Fahim Abbasi; Cindy Lamendola; Gerald M Reaven
Journal:  Am J Hypertens       Date:  2008-09-04       Impact factor: 2.689

Review 10.  Rodent models of diabetic nephropathy: their utility and limitations.

Authors:  Munehiro Kitada; Yoshio Ogura; Daisuke Koya
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.